Abstract: BI-10773, commonly known as empagliflozin, is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor originally developed for the management of type 2 diabetes mellitus (T2DM). Beyond its established glycemic control and profound cardiovascular and renal protective effects, emerging clinical and experimental evidence highlights its significant therapeutic potential in Non-alcoholic Fatty Liver Disease (NAFLD). This review synthesizes current literature on empagliflozin's role in NAFLD, detailing its pharmacological ability to reduce hepatic fat accumulation, improve liver enzymes, and modulate systemic lipid metabolism. Furthermore, it explores the molecular mechanisms driving these benefits, including AMPK activation, SIRT1 modulation, and the suppression of the NLRP3 inflammasome and oxidative stress. The review also discusses the impact of pharmacogenetics, particularly the PNPLA3 polymorphism, on treatment efficacy, outlines current clinical limitations, and provides future perspectives for the use of empagliflozin in metabolic liver diseases.
1. Introduction
BI-10773 (empagliflozin) is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), primarily utilized as a glucose-lowering agent in the management of type 2 diabetes mellitus (T2DM) [1]. By inhibiting SGLT2 in the proximal renal tubules, empagliflozin prevents renal glucose reabsorption, thereby promoting glycosuria and lowering blood glucose levels independently of insulin secretion [1]. Following landmark cardiovascular outcome trials such as EMPA-REG OUTCOME, empagliflozin has been globally recognized for its profound cardiovascular and renal benefits, including significant reductions in heart failure hospitalizations and cardiovascular mortality [1][6].
Recently, the therapeutic scope of empagliflozin has expanded beyond cardiorenal protection to include metabolic liver disorders, specifically Non-alcoholic Fatty Liver Disease (NAFLD), which is highly prevalent among patients with T2DM [1]. Clinical evidence increasingly supports the use of SGLT2 inhibitors as preferred agents for T2DM patients with concurrent NAFLD due to their ability to significantly reduce the fatty liver index and improve hepatic metabolic profiles [1].
2. Pharmacological Activity
The pharmacological activity of empagliflozin in the context of NAFLD is characterized by significant improvements in hepatic lipid accumulation and liver injury markers. In the E-LIFT randomized controlled trial, empagliflozin demonstrated a superior ability to decrease liver fat compared to standard therapy, evidenced by a significant reduction in the MRI-Proton Density Fat Fraction (PDFF) [1]. Furthermore, empagliflozin treatment is associated with a marked decrease in serum liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) [1].
Systemically, empagliflozin induces a shift in energy metabolism. It promotes fat utilization and adipose tissue browning, shifting substrate utilization away from carbohydrates toward fatty acid oxidation and ketogenesis [4][6]. This metabolic shift not only reduces overall body weight, fat mass, and epicardial fat accumulation but also mitigates lipotoxicity caused by excessive fatty acids [2][6]. Additionally, empagliflozin exhibits potent systemic anti-inflammatory effects. Meta-analyses of diabetic patients treated with SGLT2 inhibitors show significant reductions in circulating pro-inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) [2].
3. Molecular Mechanism of Action
The molecular mechanisms underlying empagliflozin's efficacy in NAFLD and associated metabolic stress involve several interconnected intracellular pathways:
AMPK Activation and mTORC1 Inhibition: Empagliflozin alters the cellular AMP:ATP ratio, leading to the activation of AMP-activated protein kinase (AMPK) [5]. The activation of AMPK, accompanied by the inhibition of the mTORC1 pathway, promotes autophagy, reduces lipid synthesis, and prevents mitochondrial fission, thereby preserving mitochondrial function under metabolic stress [4][5].
SIRT1 Modulation and Glycolysis Reduction: Empagliflozin boosts mitochondrial aerobic respiration while significantly reducing glycolytic function. This metabolic rebalancing is synergistically enhanced by the activation of sirtuin 1 (SIRT1), a nutrient-sensitive metabolic sensor that helps counteract high-glucose-induced cellular stress and lipid accumulation [2].
Suppression of Oxidative Stress and Inflammasomes: Empagliflozin attenuates oxidative stress by reducing the generation of reactive oxygen species (ROS), hydrogen peroxide, and lipid peroxides, while upregulating antioxidant defenses such as superoxide dismutase (SOD) and the Nrf2 transcription factor [5]. Furthermore, the drug increases endogenous ketone bodies like beta-hydroxybutyrate, which acts as an endogenous inhibitor of the NLRP3 inflammasome, thereby reducing the secretion of IL-1beta and IL-6 [2][6].
Transcriptional Regulation (ZFAND6): Under hyperglycemic conditions, empagliflozin reverses the downregulation of specific genes such as ZFAND6. ZFAND6 is a negative regulator of apoptosis and modulates the I-kappaB kinase/NF-kappaB signaling pathway, preventing inflammation triggered by impaired mitochondrial homeostasis [2].
4. Structure-Activity Relationship (SAR)
Empagliflozin is a C-glucoside derivative featuring a specific aglycone structure that confers high selectivity and affinity for the SGLT2 protein. In silico docking studies reveal that the glucoside moiety of empagliflozin is oriented towards the extracellular Na+ binding site of the transporter, while the aglycone part lines the extracellular opening of that site, effectively blocking the cotransport of sodium and glucose [5].
The clinical efficacy of SGLT2 inhibitors is also influenced by pharmacogenetics. The metabolism of empagliflozin and related SGLT2 inhibitors involves uridine diphosphate-glucuronosyltransferases (UGT), particularly UGT1A9. Genetic variants in the UGT1A9 gene can alter enzymatic activity, thereby influencing the pharmacokinetics and systemic exposure of the drug [3]. Furthermore, the therapeutic response in NAFLD is modulated by the PNPLA3 gene (patatin-like phospholipase domain-containing protein 3), which mediates triglyceride hydrolysis. The PNPLA3 rs738409 (p.Ile148Met) polymorphism is a known risk factor for steatohepatitis. Clinical data indicate that patients with different PNPLA3 genotypes exhibit varying degrees of hepatic fat (PDFF) reduction in response to SGLT2 inhibitor therapy, highlighting a strong genetic component to the drug's hepatic efficacy [3].
5. Current Limitations
Despite its significant benefits, the use of empagliflozin is associated with several clinical limitations and risks. The mechanism of inducing glycosuria inherently increases the risk of genital and urinary tract infections [1]. Additionally, the osmotic diuresis caused by SGLT2 inhibition can lead to volume depletion, manifesting as dehydration, hypovolemia, and hypotension, particularly in elderly patients or those on concurrent diuretic therapy [1]. There is also a recognized, albeit rare, risk of euglycemic diabetic ketoacidosis [1].
In the context of NAFLD, a major limitation is the variability in patient response due to genetic polymorphisms (such as PNPLA3), meaning that not all patients will achieve the same level of hepatic fat reduction [3]. Furthermore, while the systemic metabolic and anti-inflammatory effects are well-documented, the precise direct molecular interactions of empagliflozin within hepatic tissue remain partially hypothetical and require further targeted investigation [6].
6. Future Perspectives
Empagliflozin represents a highly promising therapeutic avenue for the management of NAFLD, particularly in patients with comorbid T2DM. Future research should focus on fully elucidating the glucose-independent mechanisms of SGLT2 inhibitors, such as their direct effects on hepatic AMPK/mTORC1 signaling, autophagy, and ketone body-mediated inflammasome suppression [4][5].
Additionally, the integration of pharmacogenetics into clinical practice holds great potential. Screening for polymorphisms in genes like PNPLA3 and UGT1A9 could enable personalized medicine approaches, optimizing empagliflozin dosing and predicting therapeutic success in NAFLD patients [3]. As clinical trials continue to explore the anti-fibrotic and anti-inflammatory properties of empagliflozin, its indication may eventually broaden to include the prevention and treatment of advanced non-alcoholic steatohepatitis (NASH) and other metabolic liver diseases, independent of diabetic status.
